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Objective. Evaluate clinical relevance of PET-CT in radiotherapy (RT) planning, clinical staging and treatment intention in head
and neck cancer (HNC)
Material and methods. This study included 80 patients treated from October 2009 to January 2013, who underwent 18F-FDG PET-CT
based RT planning HNC, with both visual and semi-quantitative image analysis performed by a nuclear medicine physician
blinded to the clinical staging provided by the radiation oncologist. Patient characteristics: average age, 58 years (range 36–82).
Location: oral cavity 15 (18.75%), oropharynx 19 (23.75%) nasopharynx 10 (12.5%), hypopharynx 11(13.75%) sinuses 1 (1.25%) and
larynx 24 (30%). Histologic type: epidermoid carcinoma 69 (86.25%), lymphoepithelioma 7 (8.75%), cystic adenoid 1 (1.25%), and
undifferentiated 3 (3.75%). Stages: I, 3 (3.75%), II, 12 (15%), III, 15 (18.75%), IV-A, 45 (56.25%) and IV-B, 5 (6.25%).
Results. Themedianprimary tumorSUVmaxwas20.65 (5.31–48.30) andmediannodal SUVmaxwas11.97 (2.30–31.90). In 21(26.25%)
patients a difference in PET-CT staging and clinical and radiological ﬁndings was found: 6 (7.5%) were previously overstaged and
15 (18.75%) were understaged. Staging changes were assessed in primary tumor, nodal involvement and distant metastases.
Changes for primary tumor staging (T) were assessed in 34 (42.5%) patients, of which 3 (3.75%) were previously overstaged and
17 (21.25%) were understaged. Nodal staging (N) was previously overstaged in 4 (5%) patients and 30 (37.5%) were restaged. A
statistical signiﬁcance (p 0.005) between the elevated nodal SUVmax (27.36) and the presence of distant metastasis was found in
2 (2.5%) patients. And due to these ﬁndings a radical treatment was dismissed in these patients.
Conclusions. The use of PET-CT in radiotherapy planning for HNC provides more accurate clinical staging, selects patients for
radical treatment and can help in target deﬁnition. To determine whether a high nodal SUVmax value is related to the presence
of distant metastases, further studies are needed on this matter.
http://dx.doi.org/10.1016/j.rpor.2013.03.254
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Background. Local control (LC), disease free survival (DFS) and overall survival (OS) improve with combined modalities, espe-
cially with concurrent chemoradiation approaches. Concurrent chemoradiation plus following chemotherapy showed a strong
beneﬁt but this scheme is less likely to be completed because of toxicity. Our aim was to ﬁnd if sequential therapy (induction
chemotherapy plus concurrent chemoradiation) had a feasible compliance with acceptable results.
Materials and methods. We retrospectively analyzed 27 patients with nonmetastatic locally advanced nasopharyngeal carcinoma
staged T1-4 N0-3 M0 treated with sequential therapy between 2006 and 2011. Patients received induction chemotherapy: 16 with
docetaxel (75mg/m2)–cisplatin (75mg/m2)–5 FU (750mg/m2) (TPF) schemeand11with cisplatin (100mg/m2)–5 FU (750mg/m2) (PF)
for 3 cycles followed by concurrent chemoradiation. Total radiation dosewas 68–70Gy, 1.8–2.0Gy/fraction. Concurrent chemother-
apy: cisplatin (100mg/m2) n=17 and carboplatin (100mg/m2) n=10. We used Kaplan–Meier actuarial method to analyze DFS and
OS. Local response is based on Recist version 1.1.
Results. Compliance to induction chemotherapy was acceptable. Only 5 (19%) patients stopped or did not complete therapy due
to toxicity (moderate to severe neutropenia: TPF n=2, PF n=3). LC 8 weeks after treatment was: complete response 53.8%, partial
response 26.9%, stable disease 12.9%, and disease progression 7.7%. Median follow up time 38 months. Mean DFS 40 months and
mean OS 62 months at time to follow up. 25 patients are alive at the moment of analysis.
Conclusions. In our study sequential therapy for locally advanced nasopharyngeal carcinoma had acceptable toxicities, low
treatment interruption and favorable results. Further recommendations and concerns must be clariﬁed in a randomized setting.
http://dx.doi.org/10.1016/j.rpor.2013.03.255
